Vantia Therapeutics is a leading research based healthcare company dedicated to improving clinical treatments through development & commercialisation of innovative medicines.

Vantia was formed in late 2007, and acquired a series of assets & people from Ferring Research Ltd in March 2008.

Vantia is a new company with 21 years experience in small molecule discovery & early development. The new Management Team led by Jim Phillips (CEO) is adding to that a Clinical Development & Commercialisation capability.

Vantia is based in Southampton University’s Science Park in the United Kingdom, where our team of 16 scientists have fully equipped facilities for Medicinal Chemistry, DMPK, and Lead Discovery.

Vantia is planning to develop its lead products over the next two years to the point where larger pharmaceutical companies will partner the programs from us.

New UK R&D company
Vantia Therapeutics, launched with backing from MVM Life Science Partners, SV Life Sciences and Novo A/S
» more